All patients
Age < 65y (younger) Age > 65y Gender, female Gender, male stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mesothelioma (MS), tremelimumab vs. placebo, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results DETERMINE, 2017 0.92 [0.76; 1.12]
0.92 [0.76 ; 1.12 ] DETERMINE, 2017 1 0% 571 NA not evaluable progression or deaths (PFS)detailed results DETERMINE, 2017 0.81 [0.67; 0.97]
0.81 [0.67 ; 0.97 ] DETERMINE, 2017 1 0% 571 NA not evaluable DCRdetailed results DETERMINE, 2017 1.39 [0.92; 2.09]
1.39 [0.92 ; 2.09 ] DETERMINE, 2017 1 0% 571 NA not evaluable objective responses (ORR)detailed results DETERMINE, 2017 4.35 [1.00; 19.05]
4.35 [1.00 ; 19.05 ] DETERMINE, 2017 1 0% 571 NA not evaluable TRAE (grade 3-4)detailed results DETERMINE, 2017 1.74 [1.22; 2.47]
1.74 [1.22 ; 2.47 ] DETERMINE, 2017 1 0% 569 NA not evaluable TRAE leading to death (grade 5)detailed results DETERMINE, 2017 1.50 [0.76; 2.95]
1.50 [0.76 ; 2.95 ] DETERMINE, 2017 1 0% 569 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results DETERMINE, 2017 0.57 [0.19; 1.73]
0.57 [0.19 ; 1.73 ] DETERMINE, 2017 1 0% 569 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results DETERMINE, 2017 3.00 [0.15; 60.20]
3.00 [0.15 ; 60.20 ] DETERMINE, 2017 1 0% 569 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Anaemia TRAE (grade 3-4)detailed results DETERMINE, 2017 1.68 [0.46; 6.16]
1.68 [0.46 ; 6.16 ] DETERMINE, 2017 1 0% 569 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Arthritis TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Asthenia TRAE (grade 3-4)detailed results DETERMINE, 2017 1.50 [0.40; 5.62]
1.50 [0.40 ; 5.62 ] DETERMINE, 2017 1 0% 569 NA not evaluable Back pain (TRAE grade 3-4)detailed results DETERMINE, 2017 0.08 [0.00; 1.64]
0.08 [0.00 ; 1.64 ] DETERMINE, 2017 1 0% 569 NA not evaluable Chills TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Colitis TRAE (grade 3-4)detailed results Out of scale DETERMINE, 2017 25.42 [1.54; 420.53]
25.42 [1.54 ; 420.53 ] DETERMINE, 2017 1 0% 569 NA not evaluable Constipation TRAE (grade 3-4)detailed results DETERMINE, 2017 0.25 [0.02; 2.74]
0.25 [0.02 ; 2.74 ] DETERMINE, 2017 1 0% 569 NA not evaluable Cough TRAE (grade 3-4)detailed results DETERMINE, 2017 0.25 [0.01; 7.42]
0.25 [0.01 ; 7.42 ] DETERMINE, 2017 1 0% 569 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results DETERMINE, 2017 2.01 [0.42; 9.56]
2.01 [0.42 ; 9.56 ] DETERMINE, 2017 1 0% 569 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results Out of scale DETERMINE, 2017 33.86 [4.65; 246.49]
33.86 [4.65 ; 246.49 ] DETERMINE, 2017 1 0% 569 NA not evaluable Dyspepsia TRAE (grade 3-4)detailed results DETERMINE, 2017 0.25 [0.01; 7.42]
0.25 [0.01 ; 7.42 ] DETERMINE, 2017 1 0% 569 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results DETERMINE, 2017 0.58 [0.33; 1.02]
0.58 [0.33 ; 1.02 ] DETERMINE, 2017 1 0% 569 NA not evaluable Epistaxis TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Fatigue TRAE (grade 3-4)detailed results DETERMINE, 2017 0.49 [0.14; 1.72]
0.49 [0.14 ; 1.72 ] DETERMINE, 2017 1 0% 569 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results DETERMINE, 2017 3.00 [0.15; 60.20]
3.00 [0.15 ; 60.20 ] DETERMINE, 2017 1 0% 569 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results DETERMINE, 2017 1.75 [0.36; 8.53]
1.75 [0.36 ; 8.53 ] DETERMINE, 2017 1 0% 569 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results DETERMINE, 2017 1.85 [0.51; 6.71]
1.85 [0.51 ; 6.71 ] DETERMINE, 2017 1 0% 569 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Myalgia TRAE (grade 3-4)detailed results DETERMINE, 2017 1.99 [0.09; 44.45]
1.99 [0.09 ; 44.45 ] DETERMINE, 2017 1 0% 569 NA not evaluable Nausea TRAE (grade 3-4)detailed results DETERMINE, 2017 2.00 [0.22; 18.02]
2.00 [0.22 ; 18.02 ] DETERMINE, 2017 1 0% 569 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.18; 5.48]
0.99 [0.18 ; 5.48 ] DETERMINE, 2017 1 0% 569 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results DETERMINE, 2017 0.25 [0.01; 7.42]
0.25 [0.01 ; 7.42 ] DETERMINE, 2017 1 0% 569 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results DETERMINE, 2017 1.99 [0.09; 44.45]
1.99 [0.09 ; 44.45 ] DETERMINE, 2017 1 0% 569 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results DETERMINE, 2017 0.89 [0.29; 2.70]
0.89 [0.29 ; 2.70 ] DETERMINE, 2017 1 0% 569 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Pruritus TRAE (grade 3-4)detailed results DETERMINE, 2017 3.00 [0.15; 60.20]
3.00 [0.15 ; 60.20 ] DETERMINE, 2017 1 0% 569 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results DETERMINE, 2017 3.00 [0.15; 60.20]
3.00 [0.15 ; 60.20 ] DETERMINE, 2017 1 0% 569 NA not evaluable Rash TRAE (grade 3-4)detailed results DETERMINE, 2017 1.99 [0.09; 44.45]
1.99 [0.09 ; 44.45 ] DETERMINE, 2017 1 0% 569 NA not evaluable Sepsis TRAE (grade 3-4)detailed results DETERMINE, 2017 3.02 [0.36; 25.23]
3.02 [0.36 ; 25.23 ] DETERMINE, 2017 1 0% 569 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results DETERMINE, 2017 1.50 [0.15; 14.48]
1.50 [0.15 ; 14.48 ] DETERMINE, 2017 1 0% 569 NA not evaluable Vomiting TRAE (grade 3-4)detailed results DETERMINE, 2017 0.87 [0.25; 3.00]
0.87 [0.25 ; 3.00 ] DETERMINE, 2017 1 0% 569 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.09; 11.04]
0.99 [0.09 ; 11.04 ] DETERMINE, 2017 1 0% 569 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-03 13:33 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 139,222,223,221
- treatments: 556